FIG 4.

Adjusted mean change from baseline over 24 weeks in (A) GHS/QoL and functioning and (B) symptoms. Adjusted mean change from baseline was calculated using an MMRM analysis, including treatment, visit, and treatment-by-visit interaction as explanatory variables and the baseline score as a covariate. Data reported are the adjusted mean change from baseline averaged over 24 weeks. Error bars represent the 95% CIs. Dotted lines represent the threshold for clinically meaningful change: an absolute change in the score of ≥10 points from the baseline score. Change from baseline in jaundice was not calculated. GHS, global health status; MMRM, mixed-effect model repeated measures; QoL, quality of life; STRIDE, Single Tremelimumab Regular Interval Durvalumab.